← Who reports today · Health Care
IQV · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 8.7% y/y to $4.37B, operating margin 11.6% vs 12.6%, net income $256M (−3.8% y/y).
Net income attributable to IQVIA Holdings Inc.
$256M
down 3.8% y/y
Revenues
$4,368M
up 8.7% y/y
Income from operations
$506M
up 0.0% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenues | $4,368 · +8.7% |
| Cost of revenues, exclusive of depreciation and amortization | $2,933 · +8.9% |
| Selling, general and administrative expenses | $574 · +12.8% |
| Depreciation and amortization | $292 · +5.8% |
| Restructuring costs | $63 · +96.9% |
| Income from operations | $506 · +0.0% · 11.6% margin |
| Interest income | $7 · −30.0% |
| Interest expense | $197 · +8.2% |
| Loss on extinguishment of debt | $3 · vs $0 |
| Other expense, net | $12 · +9.1% |
| Income before income taxes and equity in earnings (losses) of unconsolidated affiliates | $301 · −6.8% |
| Income tax expense | $60 · +7.1% · 19.9% effective rate |
| Equity in earnings (losses) of unconsolidated affiliates | $17 · vs −$1 |
| Net income attributable to noncontrolling interests | $2 · vs $0 |
| Net income attributable to IQVIA Holdings Inc. | $256 · −3.8% · $1.53/sh · 5.9% margin |
Verdict: revenue grew 8.7% y/y to $4.37B, operating margin 11.6% vs 12.6%, net income $256M (−3.8% y/y).
Operating cash flow was $558 million and free cash flow $360 million.
Source and notation
Source: IQVIA press release, 8-K EX-99.1 of 07/28/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: IQV, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “IQV Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/iqv/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/iqv/q2-2026"><img src="https://whoreportstoday.com/t/iqv/q2-2026/sankey.png" alt="IQV Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/iqv/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/iqv/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/iqv/q2-2026">IQV Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Commercial Solutions revenue was $1,793 million and R&D Solutions revenue $2,575 million, up 8.6% and 8.8% year over year.
- Operating income was $506M, a 11.6% margin vs 12.6% a year earlier.
- The effective tax rate was 19.9% vs 17.3% a year earlier.
- Diluted EPS was $1.53 vs $1.54 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
IQV — a provider of contract clinical research, healthcare data, analytics and technology to pharmaceutical, biotech and medical device companies.
In 2025 it reported three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions; from 2026 there are two, Commercial Solutions and Research & Development Solutions. · Source: annual report (Form 10-K, SEC)
More reports: ISRG · Q3 2026 · JNJ · Q3 2026 · LH · Q3 2026 · LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · MRNA · Q2 2026 · MTD · Q2 2026 · PFE · Q2 2026 · all reports